Pharmaceutical Analytical Testing Services In CRO Market Size, Share & Trends Analysis Report By Service (Bioanalytical Testing, Method Development & Validation), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global pharmaceutical analytical testing services in CRO market size was estimated at USD 7.52 billion in 2024 and is projected to grow at a CAGR of 8.61% from 2025 to 2030. This growth is primarily attributed to factors such as the growing prevalence of chronic diseases, demand for outsourcing analytical testing services, investments in pharmaceutical R&D, and a shift toward cost-efficient drug development processes across the globe.

In addition, pharmaceuticals are increasingly outsourced to CROs to utilize specialized expertise, minimize their capital investment in the infrastructure, and streamline the timelines for the drug approval process and regulatory requirements. These tests are essential throughout development, from raw materials analysis and method validation to stability studies and impurity profiling.

As CROs offer advanced analytical technologies such as mass spectrometry, NGS, Raman spectroscopy, and automation/AI for rapid and accurate testing are expected to enhance the demand for pharmaceutical analytical testing services in CROs for developing personalized and precision medicine.

Moreover, factors such as an increasing pipeline of biologics, biosimilars, advanced therapies, and rising stringent quality control to enhance pharmaceutical products' safety, efficacy, and consistency are contributing to market growth. Besides, the expanding adoption of automation, artificial intelligence, and digital data management systems like Laboratory Information Management Systems (LIMS) in CROs is anticipated to boost the efficiency and reliability of analytical testing processes. This led pharmaceutical companies to expand their partnerships with CROs for cost-saving strategies and strategic collaborations that boost innovation, reduce risk, and improve time-to-market.

Furthermore, stringent regulatory frameworks worldwide are another major driver for the pharmaceutical analytical testing services in CRO market. Regulatory authorities such as the U.S. FDA, EMA, PMDA, and WHO require comprehensive analytical validation, method development, and stability testing to enhance drug safety, efficacy, and quality. These regulations are becoming increasingly stringent, particularly for complex biologics, biosimilars, and advanced therapies, mandating in-depth characterization and impurity profiling. The implementation of ICH guidelines (Q2, Q3, Q6) and GMP/GLP standards has intensified the demand for compliant analytical methodologies. Frequent audits and regulatory inspections further influence pharmaceutical companies to engage with specialized CROs possessing global regulatory knowledge, validated infrastructure, and quality management systems, allowing risk mitigation, faster approvals, and sustained market access across geographies.

Further, the adoption of Quality by Design (QbD) principles, which emphasize a systematic approach to product development, highlights the importance of early-stage analytical characterization. Under the QbD framework, pharmaceutical companies must define Critical Quality Attributes (CQAs) and ensure that variations in raw materials or manufacturing processes do not compromise product performance. The FDA's Process Analytical Technology (PAT) initiative promotes real-time monitoring of manufacturing parameters to maintain product consistency. This regulatory push, combined with the industry's transition toward more sophisticated drug formulations, is expanding the role of CROs in pharmaceutical analytical testing. Such aforementioned factors are expected to drive the overall market demand in the near future.

Opportunity Analysis

The industry is anticipated to witness enormous growth opportunities due to the rising complexity of drug development, increased regulatory scrutiny, and growing innovation of biologics & advanced therapies. In addition, pharmaceutical and biotechnology companies are increasingly outsourcing to specialized CROs, which help them to streamline their processes and reduce costs. Besides, with the growing demand for biologics, biosimilars, and personalized medicine, the need for pharmaceutical analytical testing methods such as LC-MS/MS, HPLC, and bioanalytical assays is expected to witness a rising requirement in the global market, further propelling the market expansion.

Moreover, the globalization of clinical trials and regulatory harmonization creates a need for pharmaceutical analytical testing services in CROs with international compliance expertise. In addition, the increased product safety led pharmaceutical companies to rely on CROs. These service providers offer high-throughput and automated solutions that deliver faster and more accurate results, AI-driven data analytics for predictive insights, and biologics & gene therapy testing advancements. This partnership allows pharmaceutical companies to concentrate on their core research and development efforts. Thus, the increasing collaboration and partnerships between pharmaceutical companies and CROs offering integrated services are anticipated to drive the growth opportunities in the industry. 

Impact of U.S. Tariffs on the Global Pharmaceutical Analytical Testing Services in CRO Market

The imposition of U.S. tariffs on imported scientific equipment, reagents, and laboratory consumables has contributed to a rise in operational costs for pharmaceutical analytical testing service providers, particularly CROs. These tariffs have directly impacted the cost of high-precision instrumentation, chromatographic columns, reagents, and bioanalytical kits, many of which are sourced from international suppliers, including China and the EU. As a result, U.S. CROs face mounting cost pressures, which are passed on to pharmaceutical and biopharmaceutical sponsors through increased service pricing. This escalation in service costs strains R&D budgets, particularly for small to mid-sized sponsors, potentially limiting the scope of outsourced analytical programs. Additionally, higher costs may delay early-stage drug development, prompting a reevaluation of outsourcing strategies and supplier geographies.

In addition, these CROs are increasingly shifting towards tariff-exempt regions and exploring local sourcing options to reduce potential disruptions. Besides, rising input costs are expected to drive the CROs to renegotiate contracts with clients or to transfer the costs downstream, which can limit pricing flexibility and affect project margins. These tariffs impact is influencing the U.S. market, which has led market players to reassess their strategies regarding raw material procurement and laboratory outsourcing to avoid areas affected by tariffs.

Technological Advancements

Technological advancements are transforming pharmaceutical analytical testing services in the CRO market by enhancing precision, efficiency, and adherence to regulatory standards. Besides, techniques such as LC-MS/MS, GC-MS, and HPLC are increasingly used for complex drug profiling, impurity analysis, and stability testing, accelerating market growth. In addition, the integration of automation and robotics has significantly improved sample handling, minimized human error, and reduced turnaround times. Different technologies, such as AI and ML, are increasingly gaining attention in predictive analytics, quality control, and advanced data interpretation, particularly in processing bioanalytical and clinical trial data.

Further, digital lab platforms, including LIMS, facilitating real-time data tracking, audit trails, and streamlined regulatory reporting, which are crucial under the stringent U.S. FDA and EMA requirements, are expected to support market growth. Moreover, in biologics and cell/gene therapies, innovative bioassay platforms and NGS have become critical for analytical validation, specifically for pharmaceutical drug development. Besides, miniaturized and portable analytical instruments support decentralized testing in remote settings. These innovations enable CROs to deliver faster, cost-effective, and highly reliable services, further accelerating the drug development timelines. Thus, with the growing demand for complex therapeutics, technology will remain a competitive advantage in the Pharmaceutical analytical testing service in the CRO landscape. 

Pricing Model Analysis

The pricing model for pharmaceutical analytical testing services in CROs is adapting to the industry's evolving complexities and regulatory demands. The milestone-based pricing is widely referred to for multi-phase projects such as stability studies or method validations. This pricing model links the payments to completing specific project phases, ensuring accountability and maintaining quality control. Besides, value-based pricing links compensation to outcomes such as regulatory success, delivery speed, or data accuracy, further repaying CROs for their strategic efforts.

Moreover, the fixed-fee models provide clients with conventional budgets for standardized services, such as batch release testing or dissolution profiling. However, it necessitates precise project scoping to manage potential risks. Furthermore, subscription or retainer models are increasingly becoming popular among pharmaceutical companies with ongoing testing needs, involving a recurring fee for continuous access to CRO resources. This supports long-term partnerships and capacity planning. Thus, pricing models in the pharmaceutical analytical testing services offered by CROs provide unique opportunities for the client's development phase, service volume, and specific regulatory requirements. 

Market Concentration & Characteristics

The pharmaceutical analytical testing services in CRO market growth stage are high, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, product expansion, and regional expansion. 

The degree of innovation in the industry is high due to the growing demand for complex drug formulations, such as biologics, mRNA, and cell and gene therapies. Besides, CROs are increasingly adopting advanced technologies such as LC-MS/MS, high-resolution mass spectrometry, automation, and AI-driven data analysis. These advancements enhance accuracy, boost throughput, and maintain regulatory compliance during preclinical and clinical development stages.

The industry is driven by stringent regulatory standards, creating strong demand for validated, high-quality services. Characterized by high specialization, technological sophistication, and international operations, the market is highly concentrated. Major CROs dominate with robust regulatory capabilities and infrastructure, while niche firms grow in specialized segments. This dual structure fosters consolidation and partnership-led expansion.

The industry is experiencing moderate-to-high merger and acquisition (M&A) activity. Major players are acquiring CROs to expand their service offerings and geographic presence. These strategic acquisitions support strengthening capabilities in specific testing domains and enhancing market positions. For instance, in November 2023, Eurofins Scientific acquired Quasfar, a prominent player in the laboratory testing services in Colombia. Through this acquisition, Eurofins broadened its operational capabilities in Latin America.

The industry is characterized by steady service expansion into specialized domains like biologics, biosimilars, and cell and gene therapies. Market concentration remains moderate, with key players such as Eurofins, Labcorp, and SGS SA holding significant market shares. However, regional CROs are increasingly gaining revenue share by offering niche services and localized regulatory expertise, driving competitive fragmentation.

Regional expansion in the industry is driven by rising demand in Asia-Pacific, Latin America, and Eastern Europe due to lower operational costs and regulatory alignment. Global CROs are establishing labs and partnerships in these regions to tap into emerging markets. Despite global presence, regional market dominance varies, creating a decentralized and dynamic competitive environment.

Service Insights

On the basis of service, the industry is segmented into bioanalytical testing, method development and validation, stability testing, and other testing services. In 2024, the bioanalytical testing segment dominated the market, accounting for a revenue share of 38.48%. The segment growth is driven by stringent regulatory requirements, rising drug development complexity & approval processes, and growing demand for biologics, biosimilars, & gene therapies. In addition, analytical testing plays a critical role in drug development by quantifying drug metabolites and biosimilars within biological matter. Besides, these services are essential for pharmacokinetic (PK), pharmacodynamic (PD), and bioequivalence studies. Further, the surge in biologics pipelines, an increasing number of biosimilar trials, and demand for precise quantification of drug metabolites. Advanced technologies such as LC-MS/MS and ligand-binding assays are widely adopted for high-sensitivity detection. CROs are increasingly investing in specialized bioanalytical capabilities to support early-phase studies, adaptive trial designs, and compliance with evolving global regulatory expectations. These factors are anticipated to boost segmental demand over the estimated period.

On the other hand, the method development and validation segment is expected to grow at a considerable rate over the analysis timeframe. The method development is widely used to select and optimize analytical methods to measure the specific attributes of a drug substance or product. Analytical methods such as High Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and spectroscopy play a vital role in method development. Besides, the increasing complexity of drug formulations has increased the demand for validation protocols. In addition, the method development mainly supports regulatory compliance, drug quality, and patient safety, which is expected to drive market growth over the estimated period.

End Use Insights

On the basis of end use, the market is segmented into pharmaceutical companies, biopharmaceutical companies, and others. The pharmaceutical companies segment accounted for the largest market share in 2024. The segment growth is driven by increasing outsourcing of non-core functions to streamline operations and reduce fixed infrastructure costs. With growing drug pipelines, specifically generics and complex formulations, these companies require extensive analytical support for method validation, impurity profiling, and release testing. Outsourcing to CROs enables flexibility, scalability, and access to innovative analytical technologies. In addition, evolving regulatory scrutiny and the need for rapid product turnaround have made outsourcing a strategic imperative. Large pharmaceutical firms particularly seek long-term partnerships with CROs to ensure consistency, compliance, and global reach across multiple development programs. Such factors are expected to drive segment growth over the estimated time period.

The biopharmaceutical companies segment is expected to grow at the fastest CAGR during the forecast period. The segment is rapidly evolving, driven by rising investment in biologics and biosimilars. Besides, with the demand for a range of biopharmaceutical products, the market has witnessed continuous demand for high-quality CRO services across the globe. In addition, most of the biopharmaceutical companies are increasing relying on CROs for analytical testing across preclinical & clinical stages. As the CROs support these companies with strategy development to set biotech programs, leveraging insights from experience in clinical development across different therapeutic areas and modalities, which further contributes to market growth.

Regional Insights

North America pharmaceutical analytical testing services in CRO marketdominated the global industry with a shareof 37.19% in 2024. This growth can be attributed to the increasing demand for high-quality drug development testing and increased reliance on CROs. Besides, the rising trend towards outsourcing due to advanced technologies, strong infrastructure, and formulation development capabilities is boosting regional growth. In addition, pharmaceutical analytical testing is improving drug development and quality assurance through improved efficiency, specialization, and compliance with regulatory compliance. In addition, large pharmaceutical companies and emerging companies are outsourcing to CROs to minimize analytical testing costs, accelerate time-to-market, and access high-end equipment and regulatory knowledge. Furthermore, CROs assist complex clinical trials by providing a comprehensive range of services, including analytical testing, clinical trial management, data management, and regulatory affairs consulting, which contribute to market expansion. Moreover, the increasing demand for biosimilars and biologics and the stringent quality requirements in the pharmaceutical industry are also expected to drive the market over the estimated period.

U.S. Pharmaceutical Analytical Testing Services in CRO Market Trends

The pharmaceutical analytical testing services in CRO market in the U.S. accounted for the largest revenue share in the North America driven by the increasing complexities of drug development, the presence of well-established market players, and a rising demand for cost-effective CRO solutions. These CROs allow pharmaceutical companies to concentrate on their core strengths, such as R&D and commercialization, which helps to minimize capital expenditure on advanced laboratories while enhancing compliance with regulatory standards.

In addition, CRO services are becoming essential for pharmaceutical companies as they support optimizing clinical research and streamlining the drug development process. Besides, in the U.S., pharmaceutical companies are turning to CROs for analytical testing to reduce costs and remain competitive while maintaining high quality and compliance standards in the market. Most CROs in the U.S. are equipped with advanced technologies, including mass spectrometry, HPLC, and molecular assays, which further support meeting the demand for biologics, biosimilars, and cell and gene therapies. Furthermore, the stringent regulatory requirements established by the FDA create demand for validated, high-quality analytical testing services that comply with cGMP and GLP standards. Thus, CROs offer flexible and scalable solutions across various phases of drug development, accelerating time-to-market. Moreover, several CRO focusing on product quality, regulatory compliance, and efficient manufacturing processes are anticipated to drive market growth.

Canada pharmaceutical analytical testing services in CRO market is driven by the country‘s emergence as an outsourcing hub in pharmaceutical manufacturing and regulatory compliance. This trend is expected to drive outsourcing activities in the region. In addition, the pharmaceutical industry in Canada depends on CROs to streamline the drug development process, playing a significant role in conducting clinical trials, providing research support, and ensuring adherence to regulatory standards.

Furthermore, the rising demand for CRO service offerings and increasing R&D spending are expected to drive market growth over the estimated time period. In addition, the country’s robust regulatory framework and rising demand for GMP and GLP-compliant testing have also led pharmaceutical companies to turn to CROs for more efficient and cost-effective solutions. The increasing demand for advanced therapies and growing clinical trials are expected to drive market expansion. Moreover, the presence of a well-established healthcare system and the increasing number of pharmaceutical companies supported by both public and private sectors is expected to drive the market growth.

Europe Pharmaceutical Analytical Testing Services in CRO Market Trends:

The pharmaceutical analytical testing services in CRO market in Europe is driven by the availability of highly skilled analysts operating in GMP/GLP environments and the presence of a favorable regulatory landscape across various European countries. Besides, increasing demand for personalized medicine and a growing pipeline of drug products contribute to market growth. In addition, pharmaceutical analytical testing supports critical quality attributes and high-quality standards, offering cost-effective solutions and leveraging extensive expertise to meet diverse drug development requirements.  Moreover, the region's increased focus on clinical research is supported by the presence of diverse patient populations and the rising requirement for analytical testing for in-depth analysis of pharmacokinetics, pharmacodynamics, and the safety profiles of new drugs. Furthermore, CROs expand their capabilities with the increasing demand for specialized analytical techniques of biosimilars and biologics, which is expected to drive market growth over the estimated period.

Germany pharmaceutical analytical testing services in CRO market held the largest share in 2024. The country’s growth can be attributed to biologics, biosimilars, personalized medicine, and increased demand for CRO services. In addition, the stringent regulatory environment encourages pharmaceutical companies to engage with CROs for tailored analytical testing methods, and integrated digital solutions will further improve speed, accuracy, and data integrity. Furthermore, several strategic initiatives, such as expansion and mergers and acquisitions by outsourcing companies, are expected to drive the pharmaceutical analytical testing services in the country's CRO market. For instance, in May 2024, BioAgilytix partnered with BBI Solutions OEM Limited (BBI) to simplify and accelerate bioanalytical testing. This partnership aimed to offer innovative therapies to patients. Such innovations are expected to drive the market over the estimated time period.

The pharmaceutical analytical testing services in CRO market in the UK is anticipated to grow significantly over the forecast period. The country's growth is driven by increased focus on products' safety, efficacy, & quality and rising demand for complex biologics, biosimilars, and cell and gene therapies. The CROs in the UK are enhancing their capabilities due to rising R&D costs, time-to-market pressures, and the need for specialized analytical expertise, which contributes to market growth. Furthermore, several companies are boosting their production capabilities in the UK to strengthen their market position and expand their sector footprints. For instance, in November 2023, RSSL announced the opening of a new innovative analytical testing facility in the UK as part of its growth strategy. The new facility will increase capacity to meet growing client demand across the life science, healthcare, food, and consumer goods sectors. Such initiatives are expected to drive market growth.

Asia Pacific Pharmaceutical Analytical Testing Services in CRO Market Trends

The pharmaceutical analytical testing services in CRO market in Asia Pacificis expected to grow at the fastest CAGR over the forecast period. The region’s growth is driven by factors such as increasing drug development activities, growing investments in R&D, the presence of well-established pharmaceutical companies, and rising healthcare expenditures. In addition, strong government support in countries such as China, India, and South Korea contributes to market growth. Besides, pharmaceutical companies are increasingly outsourcing analytical testing to CROs to access high-quality, cost-effective solutions for complex biologics and innovative therapies. In addition, CROs in the region are making significant investments in advanced analytical technologies to facilitate global regulatory submissions. Besides, regulatory harmonization and growing GMP/GLP compliance are expected to drive market growth.

Furthermore, companies are launching new facilities and forming strategic partnerships to extend their offerings across various locations within the region. This expansion is expected to enhance Asia Pacific’s drug development capabilities and support the advancement of a pipeline of innovative therapies. In addition, the presence of leading pharmaceutical companies in the region is expected to drive the market over the estimated time period.

China pharmaceutical analytical testing services in CRO market is driven by a streamlined regulatory framework, cost-effective operations, and increasing global demand for complex therapeutics. Besides, the increasing incidence of chronic diseases and the growing demand for complex therapeutics are expected to drive market growth. In addition, the growing number of clinical trials and accelerated clinical timelines drive the partnership for pharmaceutical analytical testing services in CRO in the country. Besides, a strong focus on product development and quality control innovation is expected to drive market growth. Thus, domestic and international pharmaceutical companies are increasingly outsourcing their clinical trials to CROs in China, driving the demand for pharmaceutical analytical testing services in CRO market. 

The pharmaceutical analytical testing services in CRO market in Japan is attributed to an increasing focus on pharmaceutical and biopharmaceutical R&D, technological advancements, and increased concern for product safety. In addition, the demand for CRO analytical testing services supports the improvement in the efficiency of pharmaceutical companies, allowing them to concentrate on their core competencies, which will further fuel market growth. Moreover, strategic initiatives by the market players are contributing to the country’s market growth. The country’s commitment to innovation, combined with supportive government policies and a strong focus on pharmaceutical quality assurance, is anticipated to drive market growth during the forecast period. 

India pharmaceutical analytical testing services in CRO market is driven by rising demand for high-quality testing during drug development, strict regulatory standards, and technological advancements. In addition, numerous pharmaceutical and biotechnology companies are turning to CROs in India due to their advanced technologies, established infrastructure, expertise in formulation development, process optimization, and manufacturing capabilities. Furthermore, the increasing demand for efficient pharmaceutical analytical testing services in CRO services for standard product quality is anticipated to contribute significantly to market growth. 

Latin America Pharmaceutical Analytical Testing Services in CRO Market Trends

The developing pharmaceutical industry drives Latin America's pharmaceutical analytical testing services in CRO market. This is due to the increasing number of clinical trials, new therapies, emerging medications, and the rising demand for validation and analysis to ensure accuracy and reliability in testing results. In addition, the expanding pipeline of pharmaceutical drugs across diverse therapeutic areas, coupled with the growing array of regulatory requirements, has increased the need for cost-effective pharmaceutical analytical testing services. Such factors are expected to drive the market over the estimated period. 

Brazil pharmaceutical analytical testing services in CRO market is driven by evolving regulations and varying requirements for pharmaceutical products, growing demand for innovative drugs, and favorable regulatory scenarios. Besides, the requirement for innovative drugs has led to rising requirements for pharmaceutical analytical testing services, which majorly support improving product quality and enhancing manufacturing capabilities. In addition, the combination of versatility, specialized expertise, focus on emerging regulations, and commitment to quality product innovations makes the pharmaceutical analytical testing services in CROs a unique service offering for pharmaceutical companies. 

Middle East & Africa Pharmaceutical Analytical Testing Services in CRO Market Trends

The pharmaceutical analytical testing services market in the MEA region is likely to grow steadily in the forthcoming years. Regional countries such as South Africa, Saudi Arabia, the UAE, and Kuwait increasingly focus on safety assessments to enhance their healthcare systems. Besides, the rising focus on the quality drug discovery process and expanding pipeline of pharmaceutical products are expected to drive the requirements of pharmaceutical analytical testing services in CRO. In addition, the growing need for cost-effective analytical testing services will likely drive market growth. 

South Africa pharmaceutical analytical testing services in CRO market is driven by rising demand for drug production, increased government initiatives, and rising requirements for pharmaceutical analytical testing services in CRO among pharmaceutical companies. In addition, the changing market dynamics and the improving accessibility of pharmaceutical products in underserved areas are expected to contribute to market growth.

Key Pharmaceutical Analytical Testing Services in CRO Companies Insights:

Key players operating in the pharmaceutical analytical testing services in CRO market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In October 2024, SGS SA announced the expansion of its biopharmaceutical testing capabilities. This expansion enhanced advanced instrumentation & expertise to an established facility that offers outsourcing services to developers and manufacturers in the pharmaceutical, biopharmaceutical, and medical device industries.

• In June 2024, Tentamus‘s Analytical Resource Labs launched a PFAS testing service. The company’s PFAS testing service offers a targeted analysis of four analytes, such as perfluorooctanoic acid, perfluorooctanesulfonic acid, perfluorohexanesulfonic acid, and perfluorononanoic acid.

• In August 2024, SGS SA launched new bioanalytical testing services in North America. Such launches strengthened the company’s service offerings in a significant market. 

Pharmaceutical Analytical Testing Services In CRO Market Report Scope

Global Pharmaceutical Analytical Testing Services In CRO Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pharmaceutical analytical testing services in CRO market report based on service, end use and region.

• Service Outlook (Revenue, USD Million, 2018 - 2030)

  • Bioanalytical Testing

    • Clinical

    • Non-Clinical

  • Method Development & Validation

    • Extractable & Leachable

    • Impurity Method

    • Technical Consulting

    • Others

  • Stability Testing

    • Drug Substance

    • Stability Indicating Method Validation

    • Accelerated Stability Testing

    • Photostability Testing

    • Others

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical Companies

  • Biopharmaceutical Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

    • Poland

    • Switzerland

    • Austria

    • Czech Republic

    • Croatia

    • Slovenia

    • Greece

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • Argentina

    • UAE

    • Kuwait